Teva Pharmaceutical Industries (TEVA) Cash from Operations (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Operations for 18 consecutive years, with $411.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 81.06% year-over-year to $411.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (up 36.55% YoY), and the FY2025 full-year result was $1.6 billion, up 32.24% from the prior year.
• Cash from Operations improved to $411.0 million in Q2 2026 per TEVA's latest filing, from -$40.0 million in the prior quarter.
• Across five years, Cash from Operations topped out at $1.2 billion in Q4 2023 and bottomed at -$145.0 million in Q1 2023.
• Historically, Cash from Operations has averaged $345.8 million across 5 years, with a median of $275.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 195.92% in 2023, then jumped 13760.0% in 2024.
• Over 5 years, Cash from Operations stood at $973.0 million in 2022, then climbed by 21.69% to $1.2 billion in 2023, then plunged by 51.44% to $575.0 million in 2024, then surged by 101.39% to $1.2 billion in 2025, then plunged by 64.51% to $411.0 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $411.0 million, -$40.0 million, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.